XTalks

NOVEMBER 16, 2022

Ayesha also talked about Eli Lilly falling victim to a fake Twitter account that tweeted the company was offering free insulin. Lilly clarified the fake message, but the tweet has re-ignited debate about the cost of insulin in the US. Fraudulent Eli Lilly Twitter Account Announces Free Insulin.

Insulin 52

Insulin Life Science Marketing Drugs 52

XTalks

MARCH 15, 2024

LillyDirect Pharmacy Solutions, Eli Lilly’s direct-to-consumer (DTC) drugs website, is teaming up with Amazon Pharmacy to deliver select medications to people’s homes. The drugs include Lilly’s newly approved GLP-1 obesity drug Zepbound (tirzepatide), around a dozen of the company’s insulins and migraine drug Emgality (galcanezumab).

Pharmacy 111

Pharmacy Drugs Insulin Branding 111

XTalks

OCTOBER 13, 2021

The editorial team also discussed Medtronic’s expanded recalls of the remote controllers for certain models of its MiniMed insulin pumps over cybersecurity concerns, as well as its 600 series insulin pumps due to a faulty retainer ring. Medtronic Expands Two Insulin Pump Recalls, Including One Over Cybersecurity Concerns.

Insulin 45

Insulin Life Science Vaccine Vaccination 45

XTalks

MARCH 22, 2023

Tidepool recently received US Food and Drug Administration (FDA) clearance of Tidepool Loop, an automated insulin dosing app meant for the management of type 1 diabetes in patients who are six years of age and older. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 52

Life Science Insulin Drugs 52

XTalks

MARCH 17, 2025

Amylin, a hormone co-secreted with insulin, plays a key role in regulating appetite by enhancing leptins effects the hormone that signals fullness after eating. Petrelintide, Zealand Pharmas long-acting amylin analog, is currently in Phase II clinical development and is designed for once-weekly subcutaneous injections.

Hormones 59

Hormones Drugs Sales Insulin 59

XTalks

AUGUST 13, 2024

Abbott and Medtronic have struck a global partnership to make diabetes management easier for people who need regular insulin injections. Abbott’s CGM sensors will work with Medtronic’s AID algorithms to automatically adjust insulin levels based on real-time blood sugar readings. billion by 2033.

Insulin 52

Insulin FDA Approval Marketing Development 52

XTalks

NOVEMBER 22, 2022

Provention Bio’s Tzield (teplizumab) has won US Food and Drug Administration (FDA) approval to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients eight years of age and older who have stage 2 type 1 diabetes. Provention Bio came to a commercialization agreement with Sanofi last month to market the drug in the US.

Insulin 97

Insulin Drugs FDA Approval Immune Response 97

Pharmaceutical Technology

JANUARY 31, 2023

The US omnibus bill passed in late December 2022 will give the agency greater powers to regulate accelerated approval drugs, while the Inflation Reduction Act’s lowering of drug prices will create an uncertain environment for drug developers, he said. That leaves three years for pharma companies to prepare.

Drugs 130

Drugs Gene Therapy Regulation Insulin 130

XTalks

DECEMBER 13, 2024

The study will assess the drugs effects on body weight, safety and tolerability over a 42-week period. Petrelintide, administered once a week under the skin, targets obesity through its action as an amylin analog, a hormone co-secreted with insulin from the pancreas.

Drugs 102

Drugs Hormones Trials Clinical Trials 102

XTalks

NOVEMBER 23, 2022

Find out more about the drug and how it may be a gamechanger for type 1 diabetes. Read the full articles here: Tzield Gets FDA Nod to Become First Approved Drug to Delay Onset of Type 1 Diabetes. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 52

Life Science FDA Approval Vaccine Vaccination 52

XTalks

JULY 15, 2024

With the wild success of glucagon-like peptide-1 (GLP-1) drugs, Amylyx Pharmaceuticals is looking to explore the field as it has bought out avexitide, a Phase III ready GLP-1 receptor antagonist, for $35 million in an auction last month from bankrupt Eiger BioPharmaceuticals. The drug has been evaluated in five clinical trials for PBH.

Drugs 52

Drugs Insulin Life Science Marketing 52

XTalks

JULY 15, 2024

With the wild success of glucagon-like peptide-1 (GLP-1) drugs, Amylyx Pharmaceuticals is looking to explore the field as it has bought out avexitide, a Phase III ready GLP-1 receptor antagonist, for $35 million in an auction last month from bankrupt Eiger BioPharmaceuticals. The drug has been evaluated in five clinical trials for PBH.

Insulin 52

Insulin Drugs Life Science Marketing 52

XTalks

FEBRUARY 2, 2023

The US Food and Drug Administration (FDA) has recently cleared for marketing an app called Tidepool Loop which can be used with compatible devices for automated insulin dosing (AID). The Tidepool loop app involves three integral parts: an integrated continuous glucose monitor (iCGM), a controller and an insulin pump.

Insulin 52

Insulin Marketing Life Science Development 52

Pharma in Brief

AUGUST 9, 2021

On July 31, 2021, Health Canada published a Notice of Intent outlining its plan to amend the Food and Drug Regulations ( FDR ) and the Medical Devices Regulations in the spring of 2022. The proposed amendments require applicants to provide the Minister with an RMP as part of their application for a drug authorization for human use.

Regulation 98

Regulation Drugs Manufacturing Production 98

XTalks

APRIL 29, 2022

Eli Lilly announced that its obesity drug tirzepatide has scored favorably in a late-stage clinical trial, with results showing that people who took the drug lost an average of 50 pounds, or 21 percent, of their body weight compared to placebo. percent and 22.5 percent, respectively, compared to placebo.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

XTalks

SEPTEMBER 15, 2020

In addition to the vaccine, the company is also developing an investigational drug called Remygen for the regeneration of endogenous insulin production and to improve hormonal response to hypoglycemia; trials to test the treatment are currently ongoing in patients that have been living with type 1 diabetes for more than five years.

Vaccine 103

Vaccine Vaccination Insulin Trials 103

XTalks

NOVEMBER 27, 2024

According to the company’s announcement, the type 1 diabetes drug was previously produced outside the European Union (EU) by an independent manufacturer. Approved by the US Food and Drug Administration (FDA) in 2022 to delay the progression of type 1 diabetes, Sanofi received Tzield in its $2.9 It also allotted €10 million ($10.8

Production 96

Production Manufacturing Drugs Antibody 96

XTalks

MARCH 8, 2021

Lilly and Novo are longtime competitors in the diabetes drug arena, particularly in the development of glucagon-like peptide-1 (GLP-1) receptor agonist drugs. GLP-1 receptor agonists lower blood glucose levels by increasing the production of insulin. GLP-1 acts on GLP-1 receptors on insulin-producing pancreatic ?

Insulin 98

Insulin Hormones Clinical Trials Clinical Trials 98

XTalks

NOVEMBER 9, 2022

Glucagon-like peptide-1 (GLP-1) receptor agonists are a newer class of diabetes drugs that have the potential to double as weight loss drugs, widening their lucrative market potentials. While weight loss effects can vary depending on the drug, studies show that all GLP-1 meds can result in an average weight loss of about 10.5

Insulin 98

Insulin Hormones FDA Approval Sales 98

XTalks

JANUARY 16, 2023

Novo Nordisk announced in a press release last week that a label update for their type 2 diabetes treatment Rybelsus (semaglutide) was approved from the US Food and Drug Administration (FDA). Often, diabetes medication or insulin therapy are used as management tools.

Insulin 93

Insulin Regulation Development Drugs 93

XTalks

FEBRUARY 8, 2024

Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, life sciences and pharmaceutical sectors. Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics. In 2023, Ozempic was the 13 th best-selling drug globally.

Sales 52

Sales Insulin FDA Approval Drugs 52

Pharmaceutical Technology

DECEMBER 22, 2022

The main focus is the antibody-drug conjugate (ADC ), Enhertu (trastuzumab deruxtecan), which had already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Insulin 130

Insulin Production Development Genetics 130

XTalks

OCTOBER 26, 2020

Autoantibody screening involves measuring levels of islet autoantibodies (iAb) that recognize antigens found in insulin-producing pancreatic beta cells. If approved, the drug would be Provention’s first approved compound, and one of the first drugs available to patients for the delay and prevention of T1D.

Insulin 98

Insulin Packaging Packaging Doctors 98

XTalks

JANUARY 16, 2025

Linsitinib, an oral small molecule that targets the insulin-like growth factor-1 receptor (IGF-1R), is designed to address the underlying mechanisms driving thyroid eye disease. It will rival Amgens Tepezza (teprotumumab-trbw), which became the first approved treatment for thyroid eye disease with its FDA approval in 2020.

Trials 59

Trials Clinical Trials Clinical Trials Insulin 59

XTalks

JANUARY 25, 2023

Massachusetts-based TheracosBio has received US Food and Drug Administration (FDA) approval for diabetes med Brenzavvy (bexagliflozin) to help improve glycemic control in adults with type 2 diabetes. The drug is taken once a day in conjunction with diet and exercise. What is the Animal Drug Regulatory Process?

FDA Approval 52

FDA Approval Drugs Life Science Cosmetics 52

XTalks

JUNE 5, 2023

Ozempic and Wegovy, which contain the active ingredient semaglutide, were approved by the US Food and Drug Administration (FDA). GLP-1 stimulates insulin production, thus reducing blood glucose levels, and it interacts with the brain to suppress appetite and create a feeling of fullness.

FDA Approval 98

FDA Approval Containment Drugs Pharmacy 98

XTalks

DECEMBER 14, 2022

CGMs can alert diabetics sufficiently in advance of too high or low blood glucose levels, allowing the wearer to improve the situation with insulin, for example. The CGM can be integrated with insulin delivery systems and connected to devices like Apple watches and popular health apps. Dexcom, Inc. , a cellphone) every five minutes.

Insulin 98

Insulin Marketing Branding Life Science 98

XTalks

FEBRUARY 8, 2021

In order to fact-check some of these misconceptions, the US Food and Drug Administration (FDA) recently hosted a webinar on biosimilar and interchangeable biological products to help healthcare professionals understand more about these treatment options. Biosimilars are the “generic” drugs of the biopharma world. What is a Biosimilar?

Production 78

Production Insulin Branding Generic Drugs 78

XTalks

OCTOBER 22, 2021

The US Food and Drug Administration (FDA) has approved Cyltezo (adalimumab-adbm) as the first interchangeable biosimilar for Humira (adalimumab) for the treatment of several inflammatory conditions. This means AbbVie, maker of the world’s top-selling drug Humira, could be in for some stiff competition.

FDA Approval 98

FDA Approval Production Insulin Antibody 98

XTalks

MAY 13, 2021

While AbbVie’s anti-inflammatory Humira has led pharma TV ad spending for a good part of the past year, the top pharma ads this week included diabetes drug ads from Eli Lilly and Novo Nordisk. The drug is a human glucagon-like peptide-1 (GLP-1) agonist that functions to increase insulin secretion from the pancreas.

Insulin 104

Insulin Marketing Drugs Branding 104

XTalks

FEBRUARY 14, 2024

Nonetheless, the hearing did highlight important facts and problems about drug pricing in the US, putting the pharma CEOs in the hot seat. Sanders pointed out GoFundMe pages that patients had to set up to try to afford expensive drugs. Melissa Barber who has estimated that it costs just $18 to manufacture a year’s supply of the drug.

Drugs 52

Drugs Insulin Pharmacy Development 52

XTalks

NOVEMBER 3, 2022

Eli Lilly is finding itself in an enviable position with its newly launched diabetes injection Mounjaro (tirzepatide) and blockbuster diabetes med Trulicity due to temporary shortages of competitor Novo Nordisk’s diabetes drug Ozempic (semaglutide). Lilly is also looking to pitch Mounjaro as an obesity drug and directly take on Novo’s Wegovy.

Sales 98

Sales FDA Approval Production Insulin 98

XTalks

JANUARY 5, 2024

Eli Lilly launched LillyDirect this week, an online service that provides access to the company’s medicines, including its newly approved weight loss drug Zepbound (tirzepatide). Interestingly, the company’s blockbuster diabetes drug, Mounjaro (tirzepatide), is not available through the new digital service.

Drugs 59

Drugs Pharmacy Cosmetics Medicine 59

XTalks

DECEMBER 15, 2022

In September 2021, the US Food and Drug Administration (FDA) issued a partial US clinical hold on the phase III DIAGNODE-3 clinical trial of the drug. The primary endpoints of DIAGNODE-3 are: preservation of endogenous insulin producing capacity measured as stimulated C-peptide; and.

Clinical Trials 97

Clinical Trials Clinical Trials Vaccine Vaccination 97

XTalks

AUGUST 2, 2023

Pfizer’s Top 5 Best-Selling Drugs of 2022: 1) Comirnaty Comirnaty is an mRNA-based vaccine indicated for the prevention of COVID-19. Comirnaty was first approved by the US Food and Drug Administration (FDA) in August 2021 for individuals over the age of 16. billion the drug generated in 2021. billion in 2022. billion, a 26.55

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

AUGUST 30, 2024

This trend aligns with the broader surge in biotech stocks , which have outperformed many other sectors this year, fueled by a series of high-impact drug approvals, mergers and a promising pipeline of next-generation therapies. As this industry navigates evolving healthcare demands, it demonstrates remarkable resilience. Merck & Co.

Marketing 98

Marketing Production Sales Antibody 98

XTalks

JULY 17, 2024

Octreotide is a synthetic analog of somatostatin, a hormone in the body that inhibits the release of several other hormones, including growth hormone (GH), glucagon and insulin. Excess GH stimulates the secretion of insulin-like growth factor-1 (IGF-1) from the liver, which causes most of the clinical manifestations of acromegaly.

Trials 59

Trials Hormones Clinical Trials Clinical Trials 59